ROSE-Longitudinal Assessment With Neuroimaging

Launched by STATE UNIVERSITY OF NEW YORK AT BUFFALO · Oct 11, 2021

Keywords

ClinConnect Summary

The ROSE-Longitudinal Assessment With Neuroimaging trial is studying how patients recover after experiencing a type of stroke called intracerebral hemorrhage, which involves bleeding within the brain. Researchers will follow up with 250 participants from an earlier study to see how their brain function and abilities, such as thinking and movement, change over time. This will take place 12 to 24 months after the stroke, with evaluations happening at various points to identify factors that may help predict recovery or ongoing challenges.

To be eligible for this trial, participants must be at least 18 years old and have had a specific type of intracerebral hemorrhage without any other complications like brain tumors or serious injuries. Participants will undergo advanced brain imaging and assessments of their cognitive and motor skills. The study aims to gather important information that could help doctors better understand how to support recovery in stroke patients. This trial is significant because it represents one of the largest studies of its kind, focusing on long-term brain health after a stroke.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or greater, fulfillment of the criteria for Deep, Subcortical or Lobar Intracerebral Hemorrhage
• • No evidence of trauma, vascular malformation or aneurysm, or brain tumor as a cause of ICH.
• • Ability of the patient or legal representative to provide informed consent
• Exclusion Criteria:
• • Brainstem or Cerebellar ICH
• • Patients Severely Affected by the ICH, Early Mortality, Hospice, or Withdraw of Care NOT eligible for ROS